Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
small molecule
|
| gptkbp:administeredBy |
intraperitoneal injection (in animal studies)
|
| gptkbp:CASNumber |
852808-04-9
|
| gptkbp:chemicalFormula |
C42H45ClN6O5S2
|
| gptkbp:compatibleWith |
clinical use
|
| gptkbp:developedBy |
gptkb:Abbott_Laboratories
|
| gptkbp:discoveredIn |
2005
|
| https://www.w3.org/2000/01/rdf-schema#label |
ABT-737
|
| gptkbp:inducedBy |
mitochondrial outer membrane permeabilization
|
| gptkbp:inhibitedBy |
anti-apoptotic Bcl-2 family proteins
|
| gptkbp:IUPACName |
4-[(4-{[(2R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[2,3-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]amino}phenyl)amino]-4-oxobutanoic acid
|
| gptkbp:mechanismOfAction |
induces apoptosis
|
| gptkbp:molecularWeight |
813.4 g/mol
|
| gptkbp:PubChem_CID |
11364421
CHEMBL452331 |
| gptkbp:relatedTo |
gptkb:Navitoclax
|
| gptkbp:target |
gptkb:Bcl-2_protein
Bcl-w protein Bcl-xL protein |
| gptkbp:usedIn |
cancer research
|
| gptkbp:bfsParent |
gptkb:Bcl-xL
|
| gptkbp:bfsLayer |
7
|